Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves Outcomes in Pretreated Patients with Metastatic Cancer By Ogkologos - October 14, 2025 347 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROME study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Surveillance and Early Cancer Detection are Associated with Improved Survival in... September 1, 2021 Bus Driver Finds Out Teen With Cancer Can’t Afford Prom &... June 19, 2019 Adding Capivasertib to Fulvestrant Results in Longer PFS in Patients with... June 5, 2023 How to Make the Most of Your Patient Portal During Cancer November 24, 2021 Load more HOT NEWS Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint... FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Multiple... The Mediterranean Diet EMA Recommends Granting a Conditional Marketing Authorisation for Obecabtagene Autoleucel
